Shaun Bagai
Known title: Chief Executive OfficerCIK: 0001862613
Shaun Bagai's purchase track record
How the stock did after each of Shaun Bagai's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
5
of 5 since May 19, 2022
Stock higher 6 months later
80%
3 months: 80%
Median 6-month return
+2.7%
3 months: +19.0%
Beat the S&P 500
40%
median -2.0% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/17/2025 | RNXT | $9K | +18.4% | +2.4% | +10.4% |
| 8/22/2025 | RNXT | $9K | -15.3% | -2.9% | +6.8% |
| 4/15/2025 | RNXT | $7K | +46.7% | +21.1% | +23.1% |
| 4/7/2025 | RNXT | $17K | +67.1% | +69.6% | +33.1% |
| 5/19/2022 | RNXT | $11K | +19.0% | +2.7% | +1.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| RNXT | ▲ Buy | Open Market | 24,300 | — | 3/20/2026 | View on chart |
| RNXT | ▲ Buy | Open Market | 5,000 | $5K | 12/18/2025 | View on chart |
| RNXT | ▲ Buy | Open Market | 5,000 | $4K | 12/17/2025 | View on chart |
| RNXT | ▲ Buy | Open Market | 5,000 | $5K | 8/25/2025 | View on chart |
| RNXT | ▲ Buy | Open Market | 5,000 | $5K | 8/22/2025 | View on chart |
| RNXT | ▲ Buy | Open Market | 7,500 | $7K | 4/15/2025 | View on chart |
| RNXT | ▲ Buy | Open Market | 10,000 | $8K | 4/9/2025 | View on chart |
| RNXT | ▲ Buy | Open Market | 10,000 | $8K | 4/7/2025 | View on chart |
| RNXT | ▲ Buy | Open Market | 40,983 | — | 1/26/2024 | View on chart |
| RNXT | ▲ Buy | Open Market | 5,500 | $11K | 5/19/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
RenovoRx publishes peer-reviewed case series in oncology journal
RenovoRx reported that researchers at Hackensack Meridian Health’s Jersey Shore University Medical Center published a peer-reviewed case series in Case Reports in Oncology. This update highlights clinical activity involving the company's products, adding to the scientific evidence base. The stock currently trades near its 52-week low, with an average analyst target significantly higher than the current price.
RenovoRx publishes peer-reviewed case series in oncology journal. RenovoRx reported that researchers at Hackensack Meridian Health’s Jersey Shore University Medical Center published a peer-reviewed case series in Case Reports in Oncology. This update highlights clinical activity involving the company's products, adding to the scientific evidence base. The stock currently trades near its 52-week low, with an average analyst target significantly higher than the current price.